These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16137874)

  • 1. Interstitial lung disease associated with gefitinib.
    Kataoka K; Taniguchi H; Hasegawa Y; Kondoh Y; Kimura T; Nishiyama O; Imaizumi K; Kawabe T; Kume H; Shimokata K
    Respir Med; 2006 Apr; 100(4):698-704. PubMed ID: 16137874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.
    Endo M; Johkoh T; Kimura K; Yamamoto N
    Lung Cancer; 2006 May; 52(2):135-40. PubMed ID: 16574271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
    Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
    J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer.
    Shih YN; Chiu CH; Tsai CM; Perng RP
    J Chin Med Assoc; 2005 Apr; 68(4):183-6. PubMed ID: 15850069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent gefitinib-induced interstitial lung disease.
    Suzuki M; Asahina H; Konishi J; Yamazaki K; Nishimura M
    Intern Med; 2008; 47(6):533-6. PubMed ID: 18344641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
    Tammaro KA; Baldwin PD; Lundberg AS
    J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.
    Chang SC; Chang CY; Chang SJ; Yuan MK; Lai YC; Liu YC; Chen CY; Kuo LC; Yu CJ
    Clin Lung Cancer; 2013 Jan; 14(1):55-61. PubMed ID: 22607779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients.
    Beom SH; Kim DW; Sim SH; Keam B; Park JH; Lee JO; Kim TM; Lee SH; Heo DS
    Cancer Res Treat; 2016 Jan; 48(1):88-97. PubMed ID: 25761482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease.
    Yuan MK; Chang CY; Chang SC; Chang SJ; Tang GJ; Wei YF; Liu YC; Chen CY; Yu CJ
    Int J Clin Pharmacol Ther; 2011 Oct; 49(10):587-93. PubMed ID: 21961483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
    Takano T; Ohe Y; Kusumoto M; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Tamura T; Kodama T; Saijo N
    Lung Cancer; 2004 Jul; 45(1):93-104. PubMed ID: 15196739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
    Niho S; Goto K; Yoh K; Kim YH; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
    Jpn J Clin Oncol; 2006 May; 36(5):269-73. PubMed ID: 16702163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers.
    Kitajima H; Takahashi H; Harada K; Kanai A; Inomata S; Taniguchi H; Saikai T; Abe S
    Respirology; 2006 Mar; 11(2):217-20. PubMed ID: 16548909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).
    Akamatsu H; Inoue A; Mitsudomi T; Kobayashi K; Nakagawa K; Mori K; Nukiwa T; Nakanishi Y; Yamamoto N
    Jpn J Clin Oncol; 2013 Jun; 43(6):664-8. PubMed ID: 23585689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease.
    Naito Y; Tsuchiya S; Ishihara S; Minato K; Shitara Y; Takise A; Suga T; Mogi A; Yamabe K; Saito R
    Am J Clin Oncol; 2008 Aug; 31(4):340-4. PubMed ID: 18845992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib-induced lung injury successfully treated with high-dose corticosteroids.
    Seto T; Seki N; Uematsu K; Tanigaki T; Shioya S; Koboyashi T; Umemura S; Eguchi K
    Respirology; 2006 Jan; 11(1):113-6. PubMed ID: 16423212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
    Hotta K; Kiura K; Takigawa N; Yoshioka H; Harita S; Kuyama S; Yonei T; Fujiwara K; Maeda T; Aoe K; Ueoka H; Kamei H; Umemura S; Moritaka T; Segawa Y; Kawai H; Bessho A; Kato K; Tabata M; Tanimoto M
    J Thorac Oncol; 2010 Feb; 5(2):179-84. PubMed ID: 20101144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute gefitinib-induced pneumonitis.
    Ohyanagi F; Ando Y; Nagashima F; Narabayashi M; Sasaki Y
    Int J Clin Oncol; 2004 Oct; 9(5):406-9. PubMed ID: 15549594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.
    Niho S; Kubota K; Goto K; Yoh K; Ohmatsu H; Kakinuma R; Saijo N; Nishiwaki Y
    J Clin Oncol; 2006 Jan; 24(1):64-9. PubMed ID: 16382114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy.
    Aoe K; Hiraki A; Murakami T; Maeda T; Umemori Y; Katayama H; Eda R; Takeyama H
    Anticancer Res; 2005; 25(1B):415-8. PubMed ID: 15816604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.